Double-Crane Pharma Gains NMPA Approval for COVID-19 Drug CX2101A Clinical Trials
China Resources Double-Crane Pharmaceutical Co., Ltd (SHA: 600062) has announced receiving clinical trial approval from...
Biotech
China’s Pharma Firms Collaborate on Generic Version of Sun Pharma’s Carbamazepine
Several China-based pharmaceutical companies, including Shanghai Zhongxi Sunve Pharmaceutical Co. Ltd, Shanghai Anbison Lab Co.,...
Ascletis Pharma Completes Enrollment for ASC40 Phase II Acne Study
China-based Ascletis Pharma Inc. (HKG: 1672) announced the completion of enrollment of 180 patients in...
Hangzhou Polymed Biopharmaceuticals Raises Funds for Clinical Pipeline
China-based Hangzhou Polymed Biopharmaceuticals has reportedly completed a Pre-Series A+ financing round, raising an undisclosed...
Fosun Pharma’s Gland Pharma to Acquire French CDMO Cenexi for EUR 120 Million
Shanghai Fosun Pharmaceutical Group Co (SHA: 600196) announced that its India-based subsidiary, Gland Pharma Ltd...
Luye Pharma Initiates Phase II Study for LY 03014 in China
China-based Luye Pharma Group (HKG: 2186) has announced the first patient dosing in a Phase...
Trinomab Biotech Raises RMB 750 Million in Pre-IPO Financing Round
China-based Trinomab Biotech Co., Ltd reportedly raised RMB 750 million (USD 104.5 million) in a...
3D Medicines Set for IPO in Hong Kong, Aiming to Raise Up to USD 55 Million
China-based 3D Medicines Inc. (HKG: 1244) is set to make an initial public offering (IPO)...
Biocytogen and ADC Therapeutics Enter Evaluation and Option Agreement
China-based Biocytogen Pharmaceuticals (Beijing) Co., Ltd has announced an evaluation and option agreement with Swiss...
Lyvgen Biopharma Initiates Phase II Study for LVGN7409 in Advanced NSCLC
Shanghai-based immuno-oncology therapeutics specialist Lyvgen Biopharma has announced the initiation of an open-label, multi-center, randomized...
Ascentage Pharma Receives Drug Production License for Suzhou Plant
Suzhou-based Ascentage Pharma (HKG: 6855) has announced receiving a Drug Production License (A license) following...
Zhejiang Dian Diagnostics Partners with Chengdu Eastern New Area for IVD Hub
China-based Zhejiang Dian Diagnostics Co., Ltd (SHE: 300244) has announced a strategic partnership with Chengdu...
Xiling Lab Raises RMB 100 Million for ADC Development and IND Filing
Xiling Lab, a Chengdu-based drug developer specializing in catalytic synthesis technology, has reportedly raised close...
PrimeLink Bio Raises Funds for ADC Development and R&D Expansion
Shenzhen-based drug developer PrimeLink Bio has reportedly raised “hundreds of millions” of renminbi in a...
Visen Pharmaceuticals Files for Hong Kong IPO with Focus on Growth Hormone
Visen Pharmaceuticals, a China-based joint venture between Denmark-headquartered Ascendis Pharma and Chinese healthcare-focused investment firm...
FibroGen Sues Former Employees and Two Pharma Firms for Trade Secret Theft
US-based FibroGen Inc. has filed a lawsuit against two former employees, Liu Dong and Deng...
JS InnoPharm and Strategia Holdings Form JSI Ventures in Boston
Shanghai-based JS InnoPharm Ltd has announced an agreement with US firm Strategia Holdings LLC to...
IASO Biotherapeutics Partners with Umoja Biopharma to Evaluate iCIL Platform
China-based biopharma IASO Biotherapeutics has announced a research agreement with US immuno-oncology company Umoja Biopharma,...
Aosaikang’s ASKG915 Accepted for FDA Review, Targets Advanced Solid Tumors
Beijing Aosaikang Pharmaceutical Co., Ltd (SHE: 002755) has announced that its clinical trial filing for...
Legend Biotech Receives IND Approval for LB2102 CAR-T Therapy
China-based Legend Biotech Corporation (NASDAQ: LEGN) has announced receiving Investigational New Drug (IND) approval for...